Building lasting partnerships that shape the future of human health
At Accelagen, we believe the future of human health needs a fresh, future-focused approach
We believe the future of human health needs a fresh, future-focused approach. We challenge existing conventions to deliver commercially savvy and patient-centric outcomes for leading biopharmaceutical and medical device companies in the fast-growing global trials market across Australia, North America, Asia Pacific, and Europe.
Founded in 2010, Accelagen was borne out of Greg and Rosa Plunkett’s passion and career as values-driven, outcome-focussed regulatory affairs and clinical development professionals. From the outset, Accelagen has a demonstrated track record delivering services beyond a simple transaction. We focus on your end goal and design the right strategy to get you there faster, whilst contributing the out collective mission, to create a difference to the future of human health.
Employing our unique approach to people and process, we work side by side with our partners to co-create meaningful outcomes with a tangible impact on the future of human health.
We offer strategic direction and consultation from concept through to commercialisation. We prioritise understanding where you are on your journey and the broader context of impact you hope to have.
Our process is collaborative and patient-centred. It draws upon our extensive industry experience and supports you to deliver a comprehensive and robust product to market, faster.
It’s this unique and innovative approach that creates a marked difference in the outcomes we generate for you.
Our core values guide everything we do and shape how we work with our partners to create meaningful outcomes.
.svg){kind=icon}
Success the right way
Thrive together
Make a difference everyday
.svg){kind=icon}
Find better ways
Our specialist and diverse team blends expert skills in clinical development and regulatory affairs management to accelerate our partners’ ability to bring their therapies and devices to market.
Latest company news
